{Reference Type}: Journal Article
{Title}: Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression.
{Author}: Yin C;Pa Y;Li G;Chen Q;Wang X;He X;Zhou H;
{Journal}: Immunopharmacol Immunotoxicol
{Volume}: 46
{Issue}: 3
{Year}: 2024 Jun 14
{Factor}: 3.712
{DOI}: 10.1080/08923973.2024.2347315
{Abstract}: <B>UNASSIGNED: </B>Up-regulating programmed cell death ligand-1(PD-L1) expressed on tumor cells and tumor-infiltrating myeloid cells interacting with up-regulated programmed cell death-1 (PD-1) expressed on tumor-infiltrating lymphoid cells greatly hinder their tumor-inhibiting effect. It is necessary to explore the deep mechanism of this negative effect, so as to find the potential methods to improve the immunotherapy efficiency.<BR><B>UNASSIGNED: </B>In this study, we found that the PD-1 expression in lung cancer-infiltrating type II innate lymphoid cells (ILC2s) was highly up-regulated, which greatly restrained the activation and function of ILC2s. Furthermore, anti-PD-1 could restore the inhibition and effective cytokine secretion of ILC2s when co-cultured with tumor cells. In vivo studies proved that anti-PD-1 treatment promoted the activation of tumor-infiltrating ILC2s and inhibited the tumor growth of LLC-bearing nude mice.<BR><B>UNASSIGNED: </B>Our studies demonstrate a new PD-1/PD-L1 axis regulating mechanism on innate immune cells, which provide a useful direction to ILC2s-based immunotherapy to cancer diseases.